Oral supplementation with
branched-chain amino acids (BCAA;
leucine,
isoleucine, and
valine) in patients with
liver cirrhosis potentially suppresses the incidence of
hepatocellular carcinoma (HCC) and improves event-free survival. However, the detailed mechanisms of BCAA action have not been fully elucidated. BCAA were administered to atherogenic and high-fat (Ath+HF) diet-induced
nonalcoholic steatohepatitis (NASH) model mice. Liver histology,
tumor incidence, and gene expression profiles were evaluated. Ath+HF diet mice developed hepatic
tumors at a high frequency at 68 weeks. BCAA supplementation significantly improved hepatic steatosis,
inflammation,
fibrosis, and
tumors in Ath+HF mice at 68 weeks. GeneChip analysis demonstrated the significant resolution of pro-fibrotic gene expression by BCAA supplementation. The anti-fibrotic effect of BCAA was confirmed further using
platelet-derived growth factor C transgenic mice, which develop hepatic
fibrosis and
tumors. In vitro, BCAA restored the
transforming growth factor (TGF)-β1-stimulated expression of pro-fibrotic genes in hepatic stellate cells (HSC). In hepatocytes, BCAA restored TGF-β1-induced apoptosis, lipogenesis, and Wnt/β-
Catenin signaling, and inhibited the transformation of WB-F344 rat liver epithelial stem-like cells. BCAA repressed the promoter activity of TGFβ1R1 by inhibiting the expression of the
transcription factor NFY and
histone acetyltransferase p300. Interestingly, the inhibitory effect of BCAA on TGF-β1 signaling was
mTORC1 activity-dependent, suggesting the presence of negative feedback regulation from
mTORC1 to TGF-β1 signaling. Thus, BCAA induce an anti-fibrotic effect in HSC, prevent apoptosis in hepatocytes, and decrease the incidence of HCC; therefore, BCAA supplementation would be beneficial for patients with advanced
liver fibrosis with a high risk of HCC.